<?xml version="1.0" encoding="UTF-8"?><html xmlns="http://www.w3.org/1999/xhtml" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:protege="http://protege.stanford.edu/plugins/owl/protege#" xmlns:xsp="http://www.owl-ontologies.com/2005/08/07/xsp.owl#" xmlns:Thesaurus="http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#" xmlns:owl="http://www.w3.org/2002/07/owl#" xmlns:xsd="http://www.w3.org/2001/XMLSchema#" xmlns:rdfs="http://www.w3.org/2000/01/rdf-schema#" xmlns:dublincorens="http://purl.org/dc/elements/1.1/"  version="XHTML+RDFa 1.0" ><body>INFECTION AND IMMUNITY, Aug. 2008, p. 3577&#226;&#8364;&#8220;3586                                                                                       Vol. 76, No. 8 <br /> 0019-9567/08/$08.00&#226;&#171;&#185;0 doi:10.1128/IAI.00269-08 <br /> Copyright &#194;&#169; 2008, American Society Microbiology. All Rights Reserved. <br />  <br />  <br />  <br />      Rat Pneumonia Soft-Tissue Infection Models Study of <br />                    Acinetobacter baumannii Biology&#228;&#338;&#164; <br />              Thomas A. Russo,1,2,3,4,5* Janet M. Beanan,2,4 Ruth Olson,2,4 Ulrike MacDonald,2,4 <br />                  Nicole R. Luke,3,4,5 Steven R. Gill,4,5,6 Anthony A. Campagnari3,4,5 <br />       Veterans Administration Western New York Healthcare System,1 Department Medicine,2 Department Microbiology,3 <br />           The Witebsky Center Microbial Pathogenesis,4 Center Excellence Bioinformatics Life Sciences,5 and <br />              Department Oral Biology,6 University Buffalo-State University New York, Buffalo, New York 14214 <br />                                               Received 26 February 2008/Accepted 28 May 2008 <br />  <br />              Acinetobacter baumannii bacterial pathogen increasing medical importance. Little known its <br />           mechanisms pathogenesis, safe reliable agents predictable activity A. baumannii are <br />           presently nonexistent. The availability relevant animal infection models facilitate study Acineto- <br />           bacter biology. In report tested hypothesis rat pneumonia soft-tissue infection models <br />           laboratory previously used studies extraintestinal pathogenic Escherichia coli clinically <br />           relevant A. baumannii. Advantages models previously described models animals <br />           rendered neutropenic did receive porcine mucin bacterial challenge. Using A. <br />           baumannii model pathogen 307-0294 challenge pathogen, pneumonia model demonstrated the <br />           features infection critical clinically relevant model: namely, bacterial growth/clearance, an <br />           ensuing host inflammatory response, acute lung injury, and, following progressive bacterial proliferation, <br />           death respiratory failure. We able demonstrate growth 307-0294 soft-tissue <br />           infection model. Next tested hypothesis soft-tissue infection model used discriminate <br />           inherent differences virulence various A. baumannii clinical isolates. The ability A. <br />           baumannii grow and/or cleared model dependent challenge strain. We hypothesized <br />           complement important host factor protecting A. baumannii infection vivo. In support <br />           hypothesis observation serum sensitivity various A. baumannii clinical isolates in <br />           vitro roughly paralleled growth/clearance soft-tissue infection model vivo. Lastly hypothesized <br />           soft-tissue infection model serve efficient screening mechanism identifying gene <br />           essentiality drug discovery. Random mutants 307-0294 initially screened lack growth in <br />           human ascites vitro. Selected mutants subsequently used challenge soft-tissue infection model <br />           determine disrupted gene essential growth vivo. Using approach, able <span id='am-2' about='protege:TO' typeof='owl:Thing'>to</span> <br />           successfully identify number genes essential growth 307-0294 vivo. In summary, models <br />           clinically relevant used study innate virulence various Acinetobacter clinical isolates and <br />           assess potential virulence factors, vaccine candidates, drug targets vivo used for <br />           pharmacokinetic chemotherapeutic investigations. <br />  <br />  <br />    Acinetobacter species highly prevalent environment                urinary tract; intravenous devices; surgical sites; decubitus or <br /> and cultured moist skin healthy humans,                   diabetic ulcers favored sites infection. Mortality rates as- <br /> increased colonization skin respiratory gastrointestinal             sociated Acinetobacter infection range 19 54% (16). <br /> tracts occurs individuals long-term care hospital facili-             Interestingly, A. baumannii reported uncommonly <br /> ties. The overwhelming majority infections described re-               cause severe community-acquired pneumonia, usually abnor- <br /> cently acquired mainly hospitals, lesser degree               mal hosts (e.g., alcoholics), preponderance cases re- <br /> in long-term care facilities, rarely community.               ported warm humid geographic locales (1, 2, 6). Fur- <br /> Acinetobacter baumannii accounts 1 3% hospital-ac-                    ther, importance Acinetobacter infections war-related <br /> quired infections 2 10% infections intensive care units            injuries established. A. baumannii common <br /> (14, 33, 49). Both sporadic epidemic infections occur, usually              gram-negative bacillus recovered traumatic injuries the <br /> after week hospitalization (3, 13, 14, 19, 51). Impor- <br />                                                                                 lower extremities Vietnam War (48). Most recently a <br /> tantly, incidence Acinetobacter infection increasing world- <br />                                                                                 new series infections A. baumannii reported in <br /> wide (13, 16, 33). The respiratory tract, particularly ventilated <br />                                                                                 U.S. service members injured Iraq, Kuwait, Afghanistan (5, <br /> patients (6.9% hospital-acquired pneumonias 2003 based on <br />                                                                                 10, 11, 18, 44). The majority patients sustained traumatic inju- <br /> National Nosocomial Infection Surveillance System data); the <br />                                                                                 ries, infectious syndromes included soft-tissue infection, os- <br />                                                                                 teomyelitis, pneumonia, bacteremia (30). Lastly, Acineto- <br />   * Corresponding author. Mailing address: Department Medicine,              bacter emerged important pathogen survivors the <br /> Division Infectious Diseases, University Buffalo, 3435 Main St.,          Asian tsunami 2004 (15, 24). In summary, changing epide- <br /> Biomedical Research Building (Room 141), Buffalo, NY 14214. <br />                                                                                 miology incidence infections Acinetobacter establish <br /> Phone: (716) 829-2674. Fax: (716) 829-3889. E-mail: trusso@acsu <br /> .buffalo.edu.                                                                   pathogen increasing medical importance. <br />   &#228;&#338;&#164; <br />     Published ahead print 9 June 2008.                                       In centers incidence infections highly <br />  <br />                                                                          3577 <br />  3578       RUSSO ET AL.                                                                                                                               INFECT. IMMUN. <br />  <br />  <br /> antibiotic-resistant strains making treatment challenging (17,                   oxygen (FiO2) 98% administered, midline incision made <br /> 29, 32, 45, 47, 50). Particularly problematic panresistant                      peritoneum thoracic cavity. An arterial blood gas sample was <br />                                                                                     obtained descending aorta 1-ml heparinized syringe. The pulmo- <br /> strains. In 1999 New York City outbreak, 12% A. bau-                           nary vasculature flushed residual blood injecting right ventricle with <br /> mannii isolates resistant standard antimicrobials                       20 ml 1&#226;&#171;&#187; Hanks&#226;&#8364;&#8482; balanced salt solution plus 7.5% NaHCO3 (pH 7.2) using a <br /> (23). These rates higher outside United States. Safe                        22-gauge needle. Next, bronchoalveolar lavage (BAL) performed 15 ml <br /> reliable agents predictable activity A. baumannii                      normal saline (37&#194;&#176;C) administered lungs gravity a <br />                                                                                     tracheal cannula. The recovered BAL fluid (BALF) kept ice. A 500-&#226;?&#174;l <br /> are presently nonexistent. <br />                                                                                     aliquot recovered BALF removed subsequent measurement bac- <br />    The need increased understanding Acinetobacter                         terial CFU. The remaining BALF centrifuged 1,500 &#226;&#171;&#187; g pellet the <br /> pathogenesis, identification virulence factors, iden-                    cellular fraction. The supernatant removed frozen &#226;&#171;&#186;80&#194;&#176;C cyto- <br /> tification testing vaccine candidates new antimicro-                     kine/chemokine assessments (see subsequent section pulmonary inflamma- <br /> bial targets pressing (28, 46). In order                       tory response). The cellular fraction resuspended 3 ml ice-cold 1&#226;&#171;&#187; PBS, <br />                                                                                     carefully layered 2 ml cold-filtered 2% bovine serum albumin 1&#226;&#171;&#187; PBS, <br /> accomplish goals critical identify/develop relevant                  centrifuged 150 &#226;&#171;&#187; g, resuspended 4 ml ice-cold 1&#226;&#171;&#187; PBS. Lastly, the <br /> animal models infection. To date, Acinetobacter                         lungs removed kept 4&#194;&#176;C. <br /> used variety animal models, including murine (21, 22,                          (i) Assessment bacterial growth/clearance. Intact, excised post-BAL lungs <br /> 25, 26, 31, 36) guinea pig (4) pneumonia models, rat                          weighed suspended normal saline total weight 10 g (assumed <br /> thigh infection model (27), rabbit endocarditis model                         equate 10 ml). The addition saline served vehicle homogenization <br />                                                                                     generate constant volume titers easily calcu- <br /> (35). However, clinical relevance suitability                      lated. Lungs homogenized ice (three bursts 3-s duration each) <br /> models vary depending hypothesis tested. In                       using Polytron PT-2000 homogenizer (Brinkman Instruments, Westbury, NY). <br /> report tested hypothesis rat pneumonia                          Total Acinetobacter titers determined enumerating combined bacteria in <br /> soft-tissue infection models laboratory previously                     BALF plus post-BAL lung tissue described previously (41). <br />                                                                                        (ii) Assessment pulmonary host response. (a) Measurement rat <br /> used studies extraintestinal pathogenic Escherichia coli <br />                                                                                     TNF-&#226;?&#163;, IL-1&#226;?&#164;, CINC-1 levels BALF. Sandwich enzyme-linked immu- <br /> were clinically relevant studying A. baumannii infection.                       nosorbent assays utilizing commercial antibodies standards (R&amp;D Systems <br /> Next tested hypothesis soft-tissue infection                        Inc., Minneapolis, MN) employed measuring levels rat tumor necrosis <br /> model used discriminate inherent                            factor alpha (TNF-&#226;?&#163;), interleukin-1&#226;?&#164; (IL-1&#226;?&#164;), cytokine-induced neutrophil <br /> differences virulence various A. baumannii clinical iso-                      chemoattractant 1 (CINC-1) described previously (40). <br />                                                                                        (b) Measurement BALF cell counts. A 50-&#226;?&#174;l aliquot diluted 1:200 in <br /> lates. We hypothesized complement important                         Isoton II solution (Beckman Coulter), leukocyte concentration was <br /> host factor protecting A. baumannii infection vivo.                   determined using Multisizer 3 Coulter Counter (Beckman Coulter). A cy- <br /> Lastly hypothesized soft-tissue infection model                         toslide prepared diluting cells final concentration 5 &#226;&#171;&#187; 104 leuko- <br /> would serve efficient screening mechanism establish-                      cytes, using Cytospin 3 cytocentrifuge (Shandon, Pittsburgh, PA), staining with <br />                                                                                     Diff-Quik reagents (Baxter, Miami, FL), examination light microscopy <br /> ing gene essentiality drug discovery. The results suggest <br />                                                                                     (Nikon Microscope ECLIPSE 80i; Nikon Instruments Inc., Melville, NY). <br /> that models suited clinically relevant                          (iii) Assessment lung injury. Arterial blood oxygenation measured <br /> testing answering variety questions related infec-                      (ABL5; Radiometer America, Westlake, OH) reported arterial partial <br /> tions A. baumannii.                                                          pressure oxygen divided fraction inspired oxygen (PaO2/FiO2 ratio). <br />                                                                                     Albumin concentrations cell-free BAL measured enzyme-linked im- <br />                                                                                     munosorbent assay using polyclonal rabbit anti-mouse albumin antibody (a gift <br />                         MATERIALS AND METHODS                                       Daniel Remick, University Michigan, Ann Arbor, MI) horseradish <br />    Bacterial strains media. A. baumannii strain 307-0294 (blood isolate,        peroxidase-labeled goat anti-rabbit immunoglobulin (Pharmingen, San Diego, <br /> sequence type 15 [ST15], clonal group 1 based work Ecker et al. [12])     CA) (9). Rat albumin (Sigma, St. Louis, MO) used standard. <br /> was isolated patient hospitalized Erie County Medical Center, Buffalo,       Rat soft-tissue infection model. Long-Evans rats (200 250 g) anesthe- <br /> NY. A. baumannii strains 853 (OIFC031) (blood isolate, ST11, clonal group II),      tized described pneumonia model. A subcutaneous space created <br /> 855 (OIFC075) (axillary isolate, ST14, clonal group III), 900 (OIFC111) (peri-      rat injecting 50 ml air subcutaneously injecting <br /> neal isolate, ST19, clonal group undetermined), 979 (OIFC327) (environ-         mixture sterile vegetable oil (975 &#226;?&#174;l) croton oil (25 &#226;?&#174;l) space <br /> mental isolate, ST24, clonal group undetermined) isolated infected        created. After 7 days resulted encapsulated &#226;&#8364;&#339;pouch&#226;&#8364;? filled with <br /> military personnel serving Iraq Afghanistan (kindly provided David        exudative fluid (pouch fluid), mimicking subcutaneous abscess. This model <br /> Craft Paul Scott Walter Reed Army Medical Center). All strains      characterized (7, 8). It dynamic model, evidenced fact <br /> grown Luria-Bertani (LB) medium unless stated main-           neutrophils migrate pouch response appropriate stimuli. <br /> tained &#226;&#171;&#186;80&#194;&#176;C 50% LB broth 50% glycerol. Ascites plates consisted       Bacteria introduced pouch, pouch fluid easily removed <br /> 80% human ascites 20% water. Two milliliters water 15 g       time, enabling study microbial host responses. On day 8, <br /> Bacto agar autoclaved cooled 45&#194;&#176;C, 800 ml ascites kanamycin      approximately 5 &#226;&#171;&#187; 106 CFU A. baumannii strain assessed was <br /> (40-&#226;?&#174;g/ml final concentration) added, plates poured. For quanti-       injected pouches anesthetized animals, resulting estimated starting <br /> tative growth curves ascites, 100% human ascites utilized.                   pouch concentrations 1 &#226;&#171;&#187; 105 2 &#226;&#171;&#187; 105 CFU/ml. Within 1 minute the <br />    Rat pneumonia model. The rat pneumonia soft-tissue infection model           bacteria injected pouch, 0.5 ml pouch fluid removed to <br /> animal studies reviewed approved University Buffalo          measure actual starting bacterial titer. Fluid aliquots (0.5 ml) subse- <br /> Veterans Administration Institutional Animal Care Committee. An established         quently obtained anesthetized animals 3, 6, 24, 48 h initial <br /> rat (Long-Evans) model studying pulmonary damage used reported           bacterial challenge, bacterial titers determined enumerating bacte- <br /> previously (39, 41). In brief, Long-Evans rats (250 300 g) anesthetized     rial CFU pouch fluid serial 10-fold dilutions 1&#226;&#171;&#187; PBS. <br /> with 3.5% halothane 100% oxygen unconscious maintained            Serum bactericidal assay. Complement-mediated bactericidal assays per- <br /> 3.5% halothane. The trachea exposed surgically, 4-in. piece 1-0 silk   formed measuring change bacterial titer time presence of <br /> was slipped trachea facilitate instillation inoculum. The       90% active inactive (heated 56&#194;&#176;C 30 min) human serum. An input <br /> animals suspended supine position 60&#194;&#176;-incline board. Pulmonary       bacterial titer approximately 1 &#226;&#171;&#187; 105 CFU utilized, titers were <br /> instillation bacteria prepared 1&#226;&#171;&#187; phosphate-buffered saline (PBS) (pH 7.4)    measured 0, 1, 2, 3 h described previously (38, 43). <br /> was introduced intratracheally (1.2 ml/kg body weight) 1-ml syringe       Transposon mutagenesis screen lack growth ascites plates. <br /> 26-gauge needle, incision closed surgical staples. Animals    Electrocompetent cells generated growing AB307-0294 Mueller-Hinton <br /> sacrificed 3, 6, 24, 48, 72, 168 h postinoculation assessments        (MH) broth A600 0.4. Fifteen milliliters cells washed with <br /> bacterial growth/clearance, pulmonary inflammatory response, lung in-       1 ml ice-cold sterile milli-Q-filtered H2O (Millipore, Billerica, MA), followed by <br /> jury. At harvest, halothane anesthesia performed, fraction inspired        washes 10% ice-cold, sterile glycerol. After wash, cells were <br />  VOL. 76, 2008                                                                                                         A. BAUMANNII BIOLOGY               3579 <br />  <br />  <br />  <br />  <br />                                                                                          FIG. 2. <span id='am-3' about='Thesaurus:TESSE01' typeof='owl:Thing'><span id='am-4' property="Thesaurus:Preferred_Name" content="Mutation" datatype="rdf:PlainLiteral"></span><span id='am-5' property="rdfs:label" content="knockout" datatype="rdf:PlainLiteral"></span><span id='am-6' property="Thesaurus:Preferred_Name" content="cell survival" datatype="rdf:PlainLiteral"></span><span id='am-7' property="Thesaurus:code" content="TEESS07" datatype="rdf:PlainLiteral"></span><span id='am-8' property="rdfs:label" content="Novel mutation" datatype="rdf:PlainLiteral"></span><span id='am-9' property="Thesaurus:Preferred_Name" content="Nonsense mutation" datatype="rdf:PlainLiteral"></span><span id='am-10' property="Thesaurus:code" content="TEESS10" datatype="rdf:PlainLiteral"></span><span id='am-11' property="Thesaurus:code" content="TEESS04" datatype="rdf:PlainLiteral"></span><span id='am-12' property="rdfs:label" content="RNA Interference" datatype="rdf:PlainLiteral"></span><span id='am-13' property="Thesaurus:Preferred_Name" content="survival" datatype="rdf:PlainLiteral"></span><span id='am-14' property="Thesaurus:code" content="TEESS18" datatype="rdf:PlainLiteral"></span><span id='am-15' property="Thesaurus:Preferred_Name" content="lethal phenotype" datatype="rdf:PlainLiteral"></span><span id='am-16' property="rdfs:label" content="Insertion mutation" datatype="rdf:PlainLiteral"></span><span id='am-17' property="rdfs:label" content="RNA interference pathway" datatype="rdf:PlainLiteral"></span><span id='am-18' property="rdfs:label" content="Germline mutation" datatype="rdf:PlainLiteral"></span><span id='am-19' property="Thesaurus:code" content="TEESS01" datatype="rdf:PlainLiteral"></span><span id='am-20' property="Thesaurus:Preferred_Name" content="phenotype" datatype="rdf:PlainLiteral"></span><span id='am-21' property="rdfs:label" content="Targeted mutation" datatype="rdf:PlainLiteral"></span><span id='am-22' property="Thesaurus:Preferred_Name" content="null mutants" datatype="rdf:PlainLiteral"></span><span id='am-23' property="Thesaurus:code" content="TEESS06" datatype="rdf:PlainLiteral"></span><span id='am-24' property="Thesaurus:Preferred_Name" content="Induced mutation" datatype="rdf:PlainLiteral"></span><span id='am-25' property="Thesaurus:code" content="TEESS14" datatype="rdf:PlainLiteral"></span><span id='am-26' property="Thesaurus:code" content="TEESS25" datatype="rdf:PlainLiteral"></span><span id='am-27' property="rdfs:label" content="Mutation analysis" datatype="rdf:PlainLiteral"></span><span id='am-28' property="Thesaurus:code" content="TEESS05" datatype="rdf:PlainLiteral"></span><span id='am-29' property="rdfs:label" content="Gene mutation" datatype="rdf:PlainLiteral"></span><span id='am-30' property="rdfs:label" content="Frameshift mutation" datatype="rdf:PlainLiteral"></span><span id='am-31' property="rdfs:label" content="Deletion mutation" datatype="rdf:PlainLiteral"></span><span id='am-32' property="rdfs:label" content="Point mutation" datatype="rdf:PlainLiteral"></span><span id='am-33' property="Thesaurus:Preferred_Name" content="Gene knockout" datatype="rdf:PlainLiteral"></span><span id='am-34' property="Thesaurus:code" content="TEESS11" datatype="rdf:PlainLiteral"></span><span id='am-35' property="Thesaurus:Preferred_Name" content="Frameshift mutation" datatype="rdf:PlainLiteral"></span><span id='am-36' property="Thesaurus:code" content="TEESS22" datatype="rdf:PlainLiteral"></span><span id='am-37' property="rdfs:label" content="Knock-out" datatype="rdf:PlainLiteral"></span><span id='am-38' property="Thesaurus:code" content="TEESS09" datatype="rdf:PlainLiteral"></span><span id='am-39' property="Thesaurus:Preferred_Name" content="Gene mutation" datatype="rdf:PlainLiteral"></span><span id='am-40' property="Thesaurus:Preferred_Name" content="Deleterious mutation" datatype="rdf:PlainLiteral"></span><span id='am-41' property="Thesaurus:code" content="TEESS16" datatype="rdf:PlainLiteral"></span><span id='am-42' property="rdfs:label" content="Silent mutation" datatype="rdf:PlainLiteral"></span><span id='am-43' property="Thesaurus:Preferred_Name" content="Targeted mutation" datatype="rdf:PlainLiteral"></span><span id='am-44' property="rdfs:label" content="phenotype" datatype="rdf:PlainLiteral"></span><span id='am-45' property="rdfs:label" content="Deleterious mutation" datatype="rdf:PlainLiteral"></span><span id='am-46' property="rdfs:label" content="survival" datatype="rdf:PlainLiteral"></span><span id='am-47' property="Thesaurus:Preferred_Name" content="Insertion mutation" datatype="rdf:PlainLiteral"></span><span id='am-48' property="Thesaurus:code" content="TEESS08" datatype="rdf:PlainLiteral"></span><span id='am-49' property="Thesaurus:Preferred_Name" content="RNA Interference" datatype="rdf:PlainLiteral"></span><span id='am-50' property="Thesaurus:Preferred_Name" content="Point mutation" datatype="rdf:PlainLiteral"></span><span id='am-51' property="Thesaurus:Preferred_Name" content="Germline mutation" datatype="rdf:PlainLiteral"></span><span id='am-52' property="rdfs:label" content="null mutants" datatype="rdf:PlainLiteral"></span><span id='am-53' property="Thesaurus:code" content="TEESS19" datatype="rdf:PlainLiteral"></span><span id='am-54' property="Thesaurus:Preferred_Name" content="Deletion mutation" datatype="rdf:PlainLiteral"></span><span id='am-55' property="rdfs:label" content="null allele" datatype="rdf:PlainLiteral"></span><span id='am-56' property="Thesaurus:Preferred_Name" content="Silent mutation" datatype="rdf:PlainLiteral"></span><span id='am-57' property="Thesaurus:Preferred_Name" content="Knock-out" datatype="rdf:PlainLiteral"></span><span id='am-58' property="Thesaurus:code" content="TEESS03" datatype="rdf:PlainLiteral"></span><span id='am-59' property="Thesaurus:code" content="TEESS23" datatype="rdf:PlainLiteral"></span><span id='am-60' property="rdfs:label" content="Induced mutation" datatype="rdf:PlainLiteral"></span><span id='am-61' property="rdfs:label" content="Mutation" datatype="rdf:PlainLiteral"></span><span id='am-62' property="Thesaurus:Preferred_Name" content="Missense mutation" datatype="rdf:PlainLiteral"></span><span id='am-63' property="Thesaurus:Preferred_Name" content="RNA interference pathway" datatype="rdf:PlainLiteral"></span><span id='am-64' property="rdfs:label" content="cell survival" datatype="rdf:PlainLiteral"></span><span id='am-65' property="Thesaurus:Preferred_Name" content="Novel mutation" datatype="rdf:PlainLiteral"></span><span id='am-66' property="rdfs:label" content="lethal phenotype" datatype="rdf:PlainLiteral"></span><span id='am-67' property="Thesaurus:code" content="TEESS13" datatype="rdf:PlainLiteral"></span><span id='am-68' property="Thesaurus:Preferred_Name" content="Mutation analysis" datatype="rdf:PlainLiteral"></span><span id='am-69' property="rdfs:label" content="Nonsense mutation" datatype="rdf:PlainLiteral"></span><span id='am-70' property="Thesaurus:code" content="TEESS02" datatype="rdf:PlainLiteral"></span><span id='am-71' property="Thesaurus:code" content="TEESS17" datatype="rdf:PlainLiteral"></span><span id='am-72' property="Thesaurus:code" content="TEESS21" datatype="rdf:PlainLiteral"></span><span id='am-73' property="Thesaurus:Preferred_Name" content="knockout" datatype="rdf:PlainLiteral"></span><span id='am-74' property="Thesaurus:code" content="TEESS12" datatype="rdf:PlainLiteral"></span><span id='am-75' property="Thesaurus:code" content="TEESS20" datatype="rdf:PlainLiteral"></span><span id='am-76' property="rdfs:label" content="Missense mutation" datatype="rdf:PlainLiteral"></span><span id='am-77' property="Thesaurus:code" content="TEESS24" datatype="rdf:PlainLiteral"></span><span id='am-78' property="Thesaurus:Preferred_Name" content="null allele" datatype="rdf:PlainLiteral"></span><span id='am-79' property="rdfs:label" content="Gene knockout" datatype="rdf:PlainLiteral"></span><span id='am-80' property="Thesaurus:code" content="TEESS15" datatype="rdf:PlainLiteral"></span>Survival</span> rats pneumonia model post-challenge <br />                                                                                       different titers A. baumannii strain 307-0294. Rats chal- <br />   FIG. 1. Growth/clearance different titers A. baumannii strain                 lenged 7.0 &#226;&#171;&#187; 106 (n &#226;&#171;&#189; 18), 5.8 &#226;&#171;&#187; 107 (n &#226;&#171;&#189; 19), 3.5 &#226;&#171;&#187; 108 (n &#226;&#171;&#189; 19), <br /> 307-0294 rat pneumonia model. Rats challenged 7.0 &#226;&#171;&#187;                  4.3 &#226;&#171;&#187; 108 (n &#226;&#171;&#189; 18), 7.7 &#226;&#171;&#187; 109 (n &#226;&#171;&#189; 18) CFU 307-0294 by <br /> 10 , 5.8 &#226;&#171;&#187; 107, 3.5 &#226;&#171;&#187; 108, 4.3 &#226;&#171;&#187; 108, 7.7 &#226;&#171;&#187; 109 CFU 307-0294 <br />   6                                                                                   intratracheal instillation, survival recorded. There trend <br /> (blood isolate, ST15, clonal group 1) intratracheal instillation,              increased survival rats challenged 7.0 &#226;&#171;&#187; 106 5.8 &#226;&#171;&#187; 107 <br /> total lung bacterial titers determined 0, 3, 6, 24, 48, 72,               CFU compared rats challenged 7.7 &#226;&#171;&#187; 109 CFU (&amp;, P &#226;&#171;&#189; 0.03). <br /> 168 h. Data means &#226;&#171;&#190; standard errors means n &#226;&#171;&#189; 3 for <br /> each challenge titer time point. <br />  <br />                                                                                       community-acquired nosocomial pneumonia. Therefore, <br /> resuspended 75 &#226;?&#174;l used immediately stored &#226;&#171;&#186;80&#194;&#176;C prior use.     tested hypothesis immunocompetent rat pneu- <br /> EZ-Tn5&#226;&#172;?kan-2&#226;&#172;&#381;Tnp Transposome (60 ng 3 &#226;?&#174;l) (Epicentre Biotechnologies; <br />                                                                                       monia model laboratory previously used stud- <br /> catalog no. TSM99K2; Madison, WI) electroporated 75 &#226;?&#174;l electrocompe- <br /> tent AB307 (Bio-Rad Gene Pulser; 25 mF/2.5 kV/200 &#226;?&#8364;) using 0.2-cm-gap,             ies extraintestinal pathogenic E. coli clinically relevant <br /> ice-cold EPchamber (Bio-Rad Laboratories, Hercules, CA). Immediately elec-      A. baumannii (39&#226;&#8364;&#8220;42). The pertinent features gram- <br /> troporation cells resuspended S.O.C. medium (Invitrogen, Carlsbad, CA)        negative bacterial pneumonia evaluated: namely, bacte- <br /> and grown 37&#194;&#176;C 1 h. Aliquots plated MH plates supplemented        rial growth (or clearance), ensuing host inflammatory re- <br /> with kanamycin (40 &#226;?&#174;g/ml), isolated colonies purified me- <br /> dium. These 307 mutants (presumably 307-0294::Tn5&#226;&#172;?kan-2&#226;&#172;&#381;) subsequently <br />                                                                                       sponse, acute lung injury, death respiratory failure <br /> gridded ascites-kanamycin plates. 307-0294 mutants confirmed        following progressive bacterial proliferation. <br /> have minimal growth ascites-kanamycin plates numbered consec-          Bacterial growth/clearance. Rats underwent intratracheal <br /> utively stored &#226;&#171;&#186;80&#194;&#176;C.                                                          challenge various titers (7.0 &#226;&#171;&#187; 106 7.7 &#226;&#171;&#187; 109 CFU) of <br />    DNA sequencing analysis. The location transposon insertion in <br />                                                                                       A. baumannii strain 307-0294 (blood isolate, ST15, clonal <br /> mutant derivatives 307-0294 determined chromosomal sequencing. <br /> Chromosomal DNA prepared 307 mutants using              group 1) determine growth clearance occurred in <br /> Qiagen DNeasy tissue kit (Qiagen, Valencia, CA) following protocol            vivo pneumonia model 7 days (Fig. 1). Overall, <br /> gram-negative bacteria. UV spectroscopy used determine concentrations.         growth/clearance roughly correlated magnitude the <br /> DNA used immediately frozen &#226;&#171;&#186;20&#194;&#176;C. Cycle sequencing per-                challenge inoculum. For highest challenge titer (7.7 &#226;&#171;&#187; 109 <br /> formed EZ-Tn5&#226;&#172;?kan-2&#226;&#172;&#381; Transposon (Epicentre Biotechnologies) using <br /> the BigDye Terminator v3.1 Cycle Sequencing Kit (Applied Biosystems), follow- <br />                                                                                       CFU) net growth occurred 48 h, next <br /> ing protocol sequencing genomic DNA. The KAN-2 FP-1 forward primer            highest challenge titers (3.5 &#226;&#171;&#187; 108 4.3 &#226;&#171;&#187; 108 CFU) net <br /> included transposon kit used. Cycle sequencing performed            growth occurred 24 h. However, 72 h net <br /> 20-&#226;?&#174;l reaction mixtures following protocol: 96&#194;&#176;C 5 min, 96&#194;&#176;C 30 s,   clearance occurred challenge titers. By day 7, although <br /> 50&#194;&#176;C 10 s, 60&#194;&#176;C 4 min (40 cycles)/4&#194;&#176;C, ramping 1&#194;&#176;C/s. Next DNA <br />                                                                                       clearance occurred challenge titers, complete. <br /> was precipitated adding 30 ml 80% isopropanol reaction mixture. <br /> Reaction mixtures allowed stand dark 15 min               Taken together, data support contention A. <br /> centrifuged 15 min 2,097 &#226;&#171;&#187; g 4&#194;&#176;C 5415 R refrigerated centrifuge        baumannii able survive grow rat pneumonia <br /> (Eppendorf). Supernatant removed, 70% ethanol added               model dependent challenge inoculum. <br /> reaction mixture. Reaction mixtures centrifuged 15 min 2,097 &#226;&#171;&#187; g       Survival. Rats underwent intratracheal challenge vari- <br /> and 4&#194;&#176;C. Supernatants removed, reaction mixtures air dried 10 <br /> min dark. Afterwards 20 ml HiDi formamide (Applied Biosystems) was <br />                                                                                       ous titers (7.0 &#226;&#171;&#187; 106 7.7 &#226;&#171;&#187; 109 CFU) 307-0294 deter- <br /> added reaction mixture. Each vortexed 15 s. Sanger sequencing         mortality occurred vivo pneumonia model <br /> was performed 3130xl Genetic Analyzer DNA sequencer (Applied Biosys-             7 days (Fig. 2). No deaths occurred challenge with <br /> tems) according manufacturer&#226;&#8364;&#8482;s protocol. Sequence comparisons             7.0 &#226;&#171;&#187; 106 (n &#226;&#171;&#189; 18), 5.8 &#226;&#171;&#187; 107 (n &#226;&#171;&#189; 19), 4.3 &#226;&#171;&#187; 108 (n &#226;&#171;&#189; 18) <br /> performed BLAST analysis nonredundant GenBank sequences. <br />                                                                                       CFU. Two deaths occurred 24 48 h challenge <br />    Statistical analyses. Data presented means &#226;&#171;&#190; standard errors the <br /> means. P values 0.05/n (n &#226;&#171;&#189; number comparisons) considered statisti-        3.5 &#226;&#171;&#187; 108 (n &#226;&#171;&#189; 19) 7.7 &#226;&#171;&#187; 109 (n &#226;&#171;&#189; 18) CFU, respec- <br /> cally significant based Bonferroni correction multiple comparisons,        tively. There trend increased survival rats chal- <br /> and P values &#226;&#172;&#381;0.05/n &#226;&#172;?0.05 considered representing trend. In vivo     lenged 7.0 &#226;&#171;&#187; 106 5.8 &#226;&#171;&#187; 107 CFU compared rats <br /> and vitro data shown normally distributed Kolmogorov-            challenged 7.7 &#226;&#171;&#187; 109 CFU (P &#226;&#171;&#189; 0.03). These data support <br /> Smirnov normality test (P &#226;&#172;&#381; 0.10, alpha &#226;&#171;&#189; 0.05) (Prism 4 MacIntosh; Graph- <br /> Pad Software Inc.) analyzed using two-tailed unpaired t log rank <br />                                                                                       contention A. baumannii able cause lethal pul- <br /> tests.                                                                                monary infection rat pneumonia model is <br />                                                                                       dependent challenge inoculum. Further, growth/clear- <br />                                                                                       ance (see &#226;&#8364;&#339;Bacterial growth/clearance&#226;&#8364;? above), oxygenation, <br />                                   RESULTS <br />                                                                                       BALF albumin data (see &#226;&#8364;&#339;Acute lung injury&#226;&#8364;? below) sug- <br />   The rat pneumonia model clinically relevant assessing                        gest death, part, progressive bacterial <br /> Acinetobacter infection. Acinetobacter capable causing                     proliferation associated respiratory failure. <br />  3580      RUSSO ET AL.                                                                                                               INFECT. IMMUN. <br />  <br />  <br />  <br />  <br />   FIG. 3. Oxygenation concentration rats 3, 6, 24, 48, 72, 168 h post-challenge different titers A. baumannii strain 307-0294. <br /> Rats given 7.0 &#226;&#171;&#187; 106, 5.8 &#226;&#171;&#187; 107, 3.5 &#226;&#171;&#187; 108, 4.3 &#226;&#171;&#187; 108, 7.7 &#226;&#171;&#187; 109 CFU 307-0294 intratracheal instillation, aortic blood was <br /> obtained 3, 6, 24, 48, 72, 168 h determination PaO2/FiO2 (mm Hg). There trend increased oxygenation 24 h rats challenged <br /> with 7.0 &#226;&#171;&#187; 106 CFU compared rats challenged 3.5 &#226;&#171;&#187; 108 7.7 &#226;&#171;&#187; 109 CFU (&amp;, P &#226;&#171;&#189; 0.02 0.04, respectively). Data means &#226;&#171;&#190; standard <br /> errors means n &#226;&#171;&#189; 3 challenge titer time point. <br />  <br />  <br />  <br />    Acute lung injury. To determine effect A. baumannii                BALF albumin observed lowest challenge <br /> on acute lung injury, arterial oxygenation (PaO2/FiO2 ratio)                 inocula (7.0 &#226;&#171;&#187; 106 5.8 &#226;&#171;&#187; 107 CFU) (Fig. 4). The greatest <br /> and BALF albumin measured 3, 6, 24, 48, 72, 168 h                increase BALF albumin occurred 24 h three <br /> following challenge rats various titers 307-0294.                 highest 307-0294 challenge inocula (3.5 &#226;&#171;&#187; 108 7.7 &#226;&#171;&#187; 109 <br /> After challenge 307-0294, decreases oxygenation                  CFU) 6 h lowest challenge inocula (5.8 &#226;&#171;&#187; <br /> levels, reflect acute lung injury, similar               107 7.0 &#226;&#171;&#187; 106 CFU); levels decreased thereafter. There <br /> pronounced highest challenge inocula (3.5 &#226;&#171;&#187; 108               significant decrease trend significant de- <br /> to 7.7 &#226;&#171;&#187; 109 CFU). A lesser effect oxygenation observed               crease concentration BALF albumin various times <br /> with lowest challenge inocula (7.0 &#226;&#171;&#187; 106 5.8 &#226;&#171;&#187; 107               rats challenged 7.0 &#226;&#171;&#187; 106 5.8 &#226;&#171;&#187; 107 CFU compared <br /> CFU) (Fig. 3). The greatest decrease oxygenation occurred                 rats challenged 3.5 &#226;&#171;&#187; 108, 4.3 &#226;&#171;&#187; 108, 7.7 &#226;&#171;&#187; 109 CFU <br /> at 24 h highest 307-0294 challenge inocula (3.5 &#226;&#171;&#187;              (Fig. 4). These data demonstrated increase BALF <br /> 108 7.7 &#226;&#171;&#187; 109 CFU), 48 h highest challenge                albumin greatest A. baumannii able grow <br /> inoculum (5.8 &#226;&#171;&#187; 107 CFU), 72 h lowest challenge               (e.g., 307-0294 challenge inocula 3.5 &#226;&#171;&#187; 108 7.7 &#226;&#171;&#187; 109 <br /> inoculum (7.0 &#226;&#171;&#187; 106 CFU). Levels recovered                CFU) compared A. baumannii cleared (e.g., 307- <br /> back baseline. There trend increased oxygenation                0294 challenge inocula 7.0 &#226;&#171;&#187; 106 5.8 &#226;&#171;&#187; 107 CFU). <br /> at 24 h rats challenged 7.0 &#226;&#171;&#187; 106 CFU compared rats                  Host inflammatory response. To determine effect A. <br /> challenged 3.5 &#226;&#171;&#187; 108 7.7 &#226;&#171;&#187; 109 CFU (P &#226;&#171;&#189; 0.02                    baumannii pulmonary levels TNF-&#226;?&#163;, IL-1&#226;?&#164;, CINC-1 <br /> 0.04, respectively). These data demonstrated A. bau-               vivo, mediators assessed cell-free BALF su- <br /> mannii able grow (e.g., 307-0294 challenge inocula                 pernatants 3, 6, 24, 48, 72, 168 h following challenge of <br /> 3.5 &#226;&#171;&#187; 108 7.7 &#226;&#171;&#187; 109 CFU), decrease oxygenation                 rats various titers 307-0294. After challenge 307- <br /> greatest occurred quickly A. baumannii                    0294, levels TNF-&#226;?&#163;, IL-1&#226;?&#164;, CINC-1 barely mea- <br /> was cleared (e.g., 307-0294 challenge inocula 7.0 &#226;&#171;&#187; 106               surable challenge inoculum 7.0 &#226;&#171;&#187; 106 CFU, increased <br /> 5.8 &#226;&#171;&#187; 107 CFU).                                                              challenge inoculum 5.7 &#226;&#171;&#187; 107 CFU, of <br />    Leakage albumin vasculature alveolar                 similar orders magnitude challenge inocula 3.5 &#226;&#171;&#187; <br /> spaces measure acute lung injury. After challenge              108, 4.3 &#226;&#171;&#187; 108, 7.7 &#226;&#171;&#187; 109 CFU (Fig. 5A C). After <br /> with 307-0294, increases BALF albumin levels                     challenge 307-0294, TNF-&#226;?&#163; CINC-1 levels peaked at <br /> similar pronounced highest challenge                 6 h essentially limit detection 72 h (Fig. <br /> inocula (3.5 &#226;&#171;&#187; 108 7.7 &#226;&#171;&#187; 109 CFU) lesser effect                  5A C), IL-1&#226;?&#164; levels peaked 24 h the <br />  VOL. 76, 2008                                                                                                A. BAUMANNII BIOLOGY                3581 <br />  <br />  <br />  <br />  <br />    FIG. 4. BALF albumin concentration rats 3, 6, 24, 48, 72, <br /> and 168 h post-challenge different titers A. baumannii strain <br /> 307-0294. Rats given 7.0 &#226;&#171;&#187; 106, 5.8 &#226;&#171;&#187; 107, 3.5 &#226;&#171;&#187; 108, 4.3 &#226;&#171;&#187; 108, <br /> and 7.7 &#226;&#171;&#187; 109 CFU 307-0294 intratracheal instillation, and <br /> cell-free BALF obtained 3, 6, 24, 48, 72, 168 h deter- <br /> mination albumin. There significant decrease concen- <br /> tration BALF albumin 24 h rats challenged 7.0 &#226;&#171;&#187; 106 and <br /> 5.8 &#226;&#171;&#187; 107 CFU compared rats challenged 3.5 &#226;&#171;&#187; 108 CFU (*, P &#226;&#171;&#189; <br /> 0.0008 0.002, respectively) 168 h rats challenged 7.0 &#226;&#171;&#187; <br /> 106 5.8 &#226;&#171;&#187; 107 CFU compared rats challenged 3.5 &#226;&#171;&#187; 108 <br /> CFU (*, P &#226;&#171;&#189; 0.006 0.008, respectively). There trend a <br /> decrease concentration BALF albumin 6 h rats chal- <br /> lenged 7.0 &#226;&#171;&#187; 106 CFU compared rats challenged 4.3 &#226;&#171;&#187; 108 <br /> CFU (&amp;, P &#226;&#171;&#189; 0.03), 24 h rats challenged 7.0 &#226;&#171;&#187; 106 5.8 &#226;&#171;&#187; <br /> 107 CFU compared rats challenged 7.7 &#226;&#171;&#187; 109 CFU (&amp;, P &#226;&#171;&#189; 0.01 <br /> and 0.02, respectively), 168 h rats challenged 7.0 &#226;&#171;&#187; 106 <br /> CFU compared rats challenged 4.3 &#226;&#171;&#187; 108 CFU (&amp;, P &#226;&#171;&#189; 0.01). <br /> Data means &#226;&#171;&#190; standard errors means n &#226;&#171;&#189; 3 each <br /> challenge titer time point. <br />  <br />  <br />  <br /> limit detection 72 h (Fig. 5B). There significant <br /> decrease trend significant decrease TNF-&#226;?&#163;,                       FIG. 5. TNF-&#226;?&#163;, IL-1&#226;?&#164;, CINC-1 cell-free BALF concentrations <br /> IL-1-&#226;?&#164;, CINC-1 levels various times rats challenged                rats 3, 6, 24, 48, 72, 168 h post-challenge different <br /> with 7.0 &#226;&#171;&#187; 106 5.8 &#226;&#171;&#187; 107 CFU compared rats challenged                 titers A. baumannii strain 307-0294. (A) TNF-&#226;?&#163;. (B) IL-1&#226;?&#164;. <br />                                                                              (C) CINC-1. Rats given 7.0 &#226;&#171;&#187; 106, 5.8 &#226;&#171;&#187; 107, 3.5 &#226;&#171;&#187; 108, 4.3 &#226;&#171;&#187; 108, <br /> with 3.5 &#226;&#171;&#187; 108, 4.3 &#226;&#171;&#187; 108, 7.7 &#226;&#171;&#187; 109 CFU (Fig. 5). These                 7.7 &#226;&#171;&#187; 109 CFU 307-0294 (blood isolate, ST15, clonal group 1) <br /> data demonstrated challenge 307-0294 levels               intratracheal instillation, BALF obtained determination <br /> TNF-&#226;?&#163;, IL-1&#226;?&#164;, CINC-1 increased increasing chal-                     cytokine/chemokine levels 3, 6, 24, 48, 72, 168 h. (A) There <br /> lenge inocula 7.0 &#226;&#171;&#187; 106 3.5 &#226;&#171;&#187; 108 CFU reached                    significant decrease TNF-&#226;?&#163; levels 6 h rats challenged with <br /> plateau levels thereafter. Further, levels early proin-             7.0 &#226;&#171;&#187; 106 CFU compared rats challenged 4.3 &#226;&#171;&#187; 108 CFU (*, P &#226;&#171;&#189; <br />                                                                              0.01) trend decreased TNF-&#226;?&#163; levels 3 h rats challenged <br /> flammatory cytokines decreased 6 h TNF-&#226;?&#163;                       7.0 &#226;&#171;&#187; 106 CFU compared rats challenged 7.7 &#226;&#171;&#187; 109 CFU <br /> CINC-1 24 h IL-1&#226;?&#164;. These data support                      (&amp;, P &#226;&#171;&#189; 0.049), 6 h rats challenged 7.0 &#226;&#171;&#187; 106 CFU compared <br /> contention magnitude challenge inoculum               rats challenged 3.5 &#226;&#171;&#187; 108 7.7 &#226;&#171;&#187; 109 CFU (&amp;, P &#226;&#171;&#189; 0.02), at <br /> dominant factor affecting levels TNF-&#226;?&#163;, IL-1&#226;?&#164;, CINC-1.                6 h rats challenged 5.8 &#226;&#171;&#187; 107 CFU compared rats challenged <br />                                                                              4.3 &#226;&#171;&#187; 108 CFU (&amp;, P &#226;&#171;&#189; 0.04), 24 h rats challenged with <br />    Pulmonary neutrophils present BALF assessed                  7.0 &#226;&#171;&#187; 106 CFU compared rats challenged 3.5 &#226;&#171;&#187; 108 CFU (&amp;, P &#226;&#171;&#189; <br /> after challenge various titers 307-0294 (except              0.04). (B) There trend decreased IL-1&#226;?&#164; levels 24 h rats <br /> 7.7 &#226;&#171;&#187; 109 CFU challenge inoculum). Neutrophil counts peaked                  challenged 7.0 &#226;&#171;&#187; 106 CFU compared rats challenged 3.5 &#226;&#171;&#187; <br /> at 6 h decreased (Fig. 6). The total numbers               108 CFU (&amp;, P &#226;&#171;&#189; 0.04). (C) There significant decrease CINC-1 <br /> neutrophils similar challenge titers 307-             levels 3 h rats challenged 7.0 &#226;&#171;&#187; 106 CFU compared rats <br />                                                                              challenged 7.7 &#226;&#171;&#187; 109 CFU (*, P &#226;&#171;&#189; 0.007) 6 h rats <br /> 0294, challenge lowest titer (7.0 &#226;&#171;&#187; 106                challenged 7.0 &#226;&#171;&#187; 106 compared rats challenged 3.5 &#226;&#171;&#187; 108, <br /> CFU) 24, 48, 72, 168 h, significant                 4.3 &#226;&#171;&#187; 108, 7.7 &#226;&#171;&#187; 109 CFU (*, P &#226;&#171;&#189; 0.004, 0.0003, 0.004, <br /> decrease trend significant decrease num-                respectively) rats challenged 5.8 &#226;&#171;&#187; 107 CFU compared to <br /> ber neutrophils compared rats challenged                 rats challenged 3.5 &#226;&#171;&#187; 108, 4.3 &#226;&#171;&#187; 108, 7.7 &#226;&#171;&#187; 109 CFU (*, P &#226;&#171;&#189; <br />                                                                              0.007, 0.0006, 0.008, respectively). Data means &#226;&#171;&#190; standard <br /> 5.7 &#226;&#171;&#187; 107, 3.5 &#226;&#171;&#187; 108, 4.3 &#226;&#171;&#187; 108 CFU (Fig. 6). The timing                 errors means n &#226;&#171;&#189; 3 challenge titer time point. <br /> of maximal neutrophil counts corresponded timing of <br /> maximal TNF-&#226;?&#163; CINC-1 levels, unlike cytokines, neu- <br /> trophil counts decreased slowly persisted 168 h.                lenge Acinetobacter. This supports hypothesis the <br /> Further, maximal neutrophil response seen                  immunocompetent rat pneumonia model clinically relevant <br /> the lowest 307-0294 challenge titers.                                        assessing A. baumannii infection. <br />    Taken together, data demonstrate bacterial                       The rat soft-tissue infection model clinically relevant for <br /> growth, acute lung injury, appropriate host inflamma-                 assessing Acinetobacter infection. Surgical sites, ulcers, and <br /> tory response occur rat pneumonia model chal-                   patients sustained traumatic (e.g., battlefield) in- <br />  3582      RUSSO ET AL.                                                                                                              INFECT. IMMUN. <br />  <br />  <br />  <br />  <br />    FIG. 6. Neutrophil numbers BALF rats 3, 6, 24, 48, 72, 168 h post-challenge different titers A. baumannii strain 307-0294. <br /> Rats given 7.0 &#226;&#171;&#187; 106, 5.8 &#226;&#171;&#187; 107, 3.5 &#226;&#171;&#187; 108, 4.3 &#226;&#171;&#187; 108, 7.7 &#226;&#171;&#187; 109 CFU 307-0294 intratracheal instillation; BALF collected at <br /> 3, 6, 24, 48, 72, 168 h; cells harvested BALF enumerated Coulter counting. Neutrophil numbers based on <br /> leukocyte differentials obtained stained cytoslides (Materials Methods). Cell counts animals challenged 7.7 &#226;&#171;&#187; <br /> 109 CFU. There significant decrease number neutrophils 72 h rats challenged 7.0 &#226;&#171;&#187; 106 CFU compared rats challenged with <br /> 4.3 &#226;&#171;&#187; 108 CFU (*, P &#226;&#171;&#189; 0.0003) trend decrease number neutrophils 24 h rats challenged 7.0 &#226;&#171;&#187; 106 CFU compared <br /> to rats challenged 5.7 &#226;&#171;&#187; 107 4.3 &#226;&#171;&#187; 108 CFU (&amp;, P &#226;&#171;&#189; 0.019 0.041, respectively), 48 h rats challenged 7.0 &#226;&#171;&#187; 106 CFU <br /> compared rats challenged 3.5 &#226;&#171;&#187; 108 4.3 &#226;&#171;&#187; 108 CFU (&amp;, P &#226;&#171;&#189; 0.025 0.019, respectively), 72 h rats challenged 7.0 &#226;&#171;&#187; 106 <br /> CFU compared rats challenged 3.5 &#226;&#171;&#187; 108 CFU (&amp;, P &#226;&#171;&#189; 0.037), 168 h rats challenged 7.0 &#226;&#171;&#187; 106 CFU compared rats challenged <br /> with 5.7 &#226;&#171;&#187; 107 4.3 &#226;&#171;&#187; 108 CFU (&amp;, P &#226;&#171;&#189; 0.022 0.022, respectively). Data means &#226;&#171;&#190; standard errors means n &#226;&#171;&#189; 3 challenge <br /> titer time point. <br />  <br />  <br /> juries risk soft-tissue infection Acin-              mined), 979 (OIFC327) (environmental isolate, ST24, <br /> etobacter (30, 48). Therefore, tested hypothesis                 clonal group undetermined) compared 307- <br /> the immunocompetent rat soft-tissue infection model clin-                 0294 model. Three patterns observed: growth <br /> ically relevant assessing A. baumannii infection. In brief,              (979), clearance (853), variable degree clearance over <br /> a subcutaneous fluid-filled space created in-                 3 6 h followed different rates growth (855 &#226;&#172;&#381; 307-0294 &#226;&#172;&#381; <br /> oculated bacterial strain assessed, samples                   900) (Fig. 7). There significant decrease trend toward <br /> can withdrawn, bacterial titers measured                  significant decrease survival 853 900 various <br /> time (for 7 days). The growth 307-0294                       times compared 307-0294, 855, 979. This model was <br /> assessed 48 h (Fig. 7). Clearance observed                 quite sensitive differentiating abilities different A. <br /> first 6 h, followed growth achievement plateau                     baumannii strains survive vivo. Interestingly, the <br /> density 24 h. The ability 307-0294 survive host&#226;&#8364;&#8482;s               number strains assessed small, predict that <br /> defenses proliferate soft-tissue environment                 survival blood isolates 307-0294 853 the <br /> is consistent ability cause soft-tissue infection             greatest, case. These data support our <br /> humans. These data support hypothesis model                    hypothesis model used discriminate between <br /> is clinically relevant used study Acinetobacter                inherent differences virulence various A. baumannii <br /> in setting.                                                             clinical isolates. <br />    The rat soft-tissue infection model used assess                Serum sensitivity Acinetobacter isolates vitro correlates <br /> relative virulence various A. baumannii clinical isolates.                growth soft-tissue infection model. Comple- <br /> Next tested hypothesis soft-tissue infection                 ment neutrophils innate host defense factors known <br /> model used discriminate inherent                     active soft-tissue infection model (7, 8). Since <br /> differences virulence various A. baumannii clinical iso-               various strains Acinetobacter variably cleared this <br /> lates. The growth 853 (OIFC031) (blood isolate, ST11,                     model, hypothesized complement important <br /> clonal group II), 855 (axillary isolate, ST14, clonal group                  host factor protecting A. baumannii infection in <br /> III), 900 (perineal isolate, ST19, clonal group undeter-                     vivo. Therefore, serum sensitivity A. baumannii <br />  VOL. 76, 2008                                                                                               A. BAUMANNII BIOLOGY               3583 <br />  <br />  <br />  <br />  <br />   FIG. 7. Growth/clearance A. baumannii strains 307-0294, 853, 855, 900, 979 rat soft-tissue infection model. Rats prepared <br /> and challenged bacterial strains assessed described Materials Methods. Bacterial titers determined 0, 3, 6, 24, and <br /> 48 h. There significant decrease trend significant decrease survival 853 900 various times compared 307-0294, 855, <br /> and 979. Data means &#226;&#171;&#190; standard errors means n &#226;&#171;&#189; 4 9. *, 853 compared 307-0294, P &#226;&#172;? 0.001 0.0005 3 6 h, <br /> respectively; *, 853 compared 855, P &#226;&#171;&#189; 0.0004 48 h; *, 853 compared 979, P &#226;&#171;&#189; 0.0005 0.003 24 48 h, respectively. #, 853 <br /> compared 307-0294, P &#226;&#171;&#189; 0.045 24 h; #, 853 compared 855, P &#226;&#171;&#189; 0.03 24 h; #, 853 compared 979, P &#226;&#171;&#189; 0.02 0.03 3 6 h, <br /> respectively; *, 900 compared 307-0294, P &#226;&#171;&#189; 0.007 24 h; *, 900 compared 855, P &#226;&#171;&#189; 0.004 &#226;&#172;?0.0001 24 48 h, respectively; *, 900 <br /> compared 979, P &#226;&#171;&#189; 0.002, 0.005, &#226;&#172;?0.0001, &#226;&#172;?0.0001 3, 6, 24, 48 h, respectively; #, 900 compared 307-0294, P &#226;&#171;&#189; 0.019 48 h. (Inset) <br /> Enlargement data 307-0294, 855, 979 0 6 h. There trend significant difference growth 307-0294 and <br /> 855 compared 979. *, 855 compared 979, P &#226;&#171;&#189; 0.005; #, 307-0294 compared 979, P &#226;&#171;&#189; 0.02. <br />  <br />  <br />  <br />  <br /> strains 307-0294, 853, 855, 900, 979 assessed over <br /> 3 h vitro (Fig. 8). All strains grew similarly 90% serum <br /> that heated 56&#194;&#176;C 30 min inactivate comple- <br /> ment-mediated killing LB medium (data shown). <br /> When strains exposed 90% active serum, the <br /> growth 307-0294, 855, 900 similar. In contrast, <br /> 853 underwent approximate 2-log killing 900 under- <br /> went approximate 0.5-log killing followed recovery to <br /> the starting titer 3 h; differences significant <br /> compared 307-0294, 855, 979. These data roughly <br />                                                                                FIG. 8. Effect 90% normal human serum viability the <br /> correlate growth/clearance soft-tissue infection                A. baumannii strains 307-0294, 853, 855, 900, 979 vitro. Assays <br /> model (Fig. 7). However, soft-tissue infection model                performed described Materials Methods. All strains <br /> more discriminatory, 307-0294, 855, 979 demon-                     assessed presence 90% heat-inactivated (56&#194;&#176;C for <br /> strating differing growth/clearance capabilities,                30 min) normal human serum, growth rates similar; <br /> the serum sensitivity assay, survival capabilities 307-              therefore, data shown. The survival 853 900 was <br />                                                                             significantly decreased compared 307-0294, 855, 979. <br /> 0294, 855, 979 similar. This surprising               Data means &#226;&#171;&#190; standard errors means n &#226;&#171;&#189; 4 6. *, 853 <br /> multiple host defense factors (e.g., professional phagocytes                compared 307-0294, 855, 979. P &#226;&#172;?0.0001 comparisons <br /> and antimicrobial peptides) addition complement                   853 307-0294 979. P &#226;&#172;?0.0001, 0.0006, 0.002 for <br /> present soft-tissue infection model. Nonetheless,                    853 compared 855 1, 2, 3 h, respectively. #, 900 compared <br />                                                                             307-0294, 855, 979. P &#226;&#172;? 0.0001, 0.0006, &#226;&#172;?0.0001 900 <br /> these data support hypothesis complement                    compared 307-0294; P &#226;&#171;&#189; 0.002, 0.008, 0.009 900 compared <br /> host defense factor contributes clearance A.                 855; P &#226;&#171;&#189; 0.0004, &#226;&#172;?0.0001, &#226;&#172;? 0.0001 900 compared 979 for <br /> baumannii vivo.                                                          1, 2, 3 h, respectively. <br />  3584     RUSSO ET AL.                                                                                                        INFECT. IMMUN. <br />  <br />  <br />                                                                          ratory previously used studies extraintestinal patho- <br />                                                                          genic E. coli clinically relevant assessing A. baumannii <br />                                                                          (37, 41, 42). The lung important site Acinetobacter <br />                                                                          infection humans, challenge A. baumannii, <br />                                                                          pneumonia model demonstrated features in- <br />                                                                          fection critical clinically relevant model: namely, <br />                                                                          bacterial growth/clearance, ensuing host inflammatory re- <br />                                                                          sponse, acute lung injury, death respiratory failure <br />                                                                          following progressive bacterial proliferation (Fig. 1 6). Soft <br />                                                                          tissue increasingly recognized important site of <br />                                                                          Acinetobacter infection battlefield injuries, surgical sites, and <br />   FIG. 9. Growth/clearance A. baumannii strain 307-0294 its <br /> mutant derivative 307.5 rat soft-tissue infection model. Rats     ulcers (5, 11, 18). We able demonstrate growth of <br /> were prepared challenged bacterial strains assessed   307-0294 soft-tissue infection model, occurs soft- <br /> as described Materials Methods. Bacterial titers deter-      tissue infection, supporting hypothesis. We also <br /> mined 0, 3, 6, 24, 48 h.                                          hypothesized soft-tissue infection model used <br />                                                                          discriminate inherent levels virulence pos- <br />                                                                          sessed various Acinetobacter strains. In support this, var- <br />    The rat soft-tissue infection model used efficiently        ious patterns growth observed Acinetobacter <br /> assess gene essentiality vivo. Because safe reliable agents           strains tested (Fig. 7). Although scope this <br /> with predictable activity A. baumannii presently             report, biologic data used conjunction with <br /> nonexistent, need identify new antimicrobial tar-          molecular epidemiologic data means predicting the <br /> gets Acinetobacter. Although multiple approaches accom-            virulence Acinetobacter isolates. Given variable growth <br /> plish goal exist, starting point strategy           Acinetobacter strains soft-tissue infection model and <br /> identify Acinetobacter genes essential growth. The rat soft-         fact complement active host defense factor this <br /> tissue infection model efficient model assessing vivo       site, hypothesized complement important host <br /> growth/survival multiple samples obtained                 factor protecting A. baumannii infection vivo. <br /> <span id='am-1' about='protege:FROM' typeof='owl:Thing'>from</span> single animal time. Therefore, hypothesized               Growth/clearance A. baumannii strains soft-tissue <br /> that soft-tissue infection model serve effective         infection model roughly correlated growth/clearance in <br /> screening tool establishing gene essentiality drug dis-          vitro serum sensitivity studies (Fig. 8), supporting this <br /> covery. We randomly mutagenized 307-0294 using trans-                hypothesis. Lastly, supported hypothesis soft- <br /> poson EZ-Tn5&#226;&#172;?kan-2&#226;&#172;&#381;. Mutants isolated MH plates con-                  tissue infection model used establish essenti- <br /> taining kanamycin subsequently gridded ascites                 ality Acinetobacter genes vivo, important characteristic <br /> plates supplemented kanamycin. Chromosomal sequenc-                 potential drug targets (Fig. 9). Although did utilize <br /> ing (using primers ends EZ-Tn5&#226;&#172;?kan-2&#226;&#172;&#381;)                   models assess vaccine candidates virulence factors, <br /> performed mutants displayed minimal growth              self-evident used purpose well. <br /> ascites plates, enabling localization transposon in-             The models described report certain advantages <br /> sertion. One mutants (307.5) contains transposon              previously described Acinetobacter animal infection <br /> insertion gene codes phosphoribosylaminoimid-            models (4, 21, 22, 25&#226;&#8364;&#8220;27, 31, 36). First, critical able <br /> azole-succinocarboxamide synthase. Quantitative growth curves            bacterial growth significant period time a <br /> performed LB medium demonstrated differ-            pneumonia model. In rat model, highest challenge <br /> ence growth 307-0294 307.5 (data                      inocula able demonstrate growth 24 48 h <br /> shown). To test hypothesis soft-tissue infection            post-bacterial challenge (Fig. 1). Further, highest chal- <br /> model used establish gene essentiality vivo,           lenge inocula rats succumbed infection (Fig. 2). Given <br /> assessed growth AB307.5 model (Fig. 9). 307.5,            challenge inocula significant acute lung injury also <br /> a mutant derivative 307-0294, cleared, sup-               occurred (Fig. 3 4), reasonable infer these <br /> porting hypothesis.                                                  animals died respiratory insufficiency (as opposed &#226;&#8364;&#339;cy- <br />                                                                          tokine storm&#226;&#8364;?). Since did perform blood cultures in <br />                           DISCUSSION                                     animals, exclude possibility concomitant <br />                                                                          bacteremia, contribute mortality this <br />    Acinetobacter pathogen increasing medical impor-              setting. However, bacteremia did occur ani- <br /> tance (13, 14, 19, 33). Little known mechanisms          mals, bacteremia occurs severe pneumonia humans <br /> pathogenesis, vaccine candidates identified,           result does make model relevant. Taken <br /> an increasing proportion strains highly resistant an-          together, data support model particularly <br /> timicrobials (29, 32). The availability clinically relevant an-       relevant studying aspects Acinetobacter pneumonia: <br /> imal infection models facilitate studies innate vir-         namely, bacterial growth/clearance, acute lung injury, the <br /> ulence various Acinetobacter clinical isolates, potential             host response. In contrast, bacteria cleared murine <br /> virulence factors, vaccine candidates, drug targets vivo          pneumonia models. Therefore, majority Acinetobacter <br /> and used pharmacokinetic chemotherapeutic                 murine pneumonia models reported date, animals <br /> investigations. In report tested hypotheses         received porcine mucin bacterial challenge (4, 25, 26, <br /> rat pneumonia soft-tissue infection models labo-            34, 36) rendered neutropenic (20, 21), permutations <br />  VOL. 76, 2008                                                                                                            A. BAUMANNII BIOLOGY                     3585 <br />  <br />  <br /> that present patients develop Acineto-                          4. Bernabeu-Wittel, M., C. Pichardo, A. Garcia-Curiel, M. E. Pachon-Ibanez, <br />                                                                                        J. Ibanez-Martinez, M. E. Jimenez-Mejias, J. Pachon. 2005. Pharma- <br /> bacter pneumonia. In report used murine model,                              cokinetic/pharmacodynamic assessment in-vivo efficacy imipenem <br /> Acinetobacter grew 4 h underwent significant                        combination amikacin treatment experimental <br /> clearance 24 h (22). A major advantage soft-tissue                           multiresistant Acinetobacter baumannii pneumonia. Clin. Microbiol. Infect. <br />                                                                                        11:319&#226;&#8364;&#8220;325. <br /> infection model multiple sampling performed                          5. Centers Disease Control Prevention. 2004. Acinetobacter baumannii <br /> over time animal, making time cost efficient                        infections patients military medical facilities treating injured U.S. <br /> initial assessment strains vivo. In contrast, pneu-                       service members, 2002&#226;&#8364;&#8220;2004. MMWR Morb. Mortal. Wkly. Rep. 53:1063&#226;&#8364;&#8220; <br />                                                                                        1066. <br /> monia models thigh infection model (27) animals need                         6. Chen, M. Z., P. R. Hsueh, L. N. Lee, C. J. Yu, P. C. Yang, K. T. Luh. <br /> be euthanized measurement bacterial growth/clearance,                           2001. Severe community-acquired pneumonia Acinetobacter bauman- <br /> injury, host response. Further, thigh infection                         nii. Chest 120:1072&#226;&#8364;&#8220;1077. <br />                                                                                     7. Dalhoff, A., G. Frank, G. Luckhaus. 1982. The granuloma pouch: in <br /> model animals rendered neutropenic (27). Although                             vivo model pharmacokinetic chemotherapeutic investigations. I. Bio- <br /> lungs soft tissue clearly different host environments                          chemical histological characterization. Infection 10:354&#226;&#8364;&#8220;360. <br /> that contain different growth host defense factors, clinical                    8. Dalhoff, A., G. Frank, G. Luckhaus. 1983. The granuloma pouch: in <br />                                                                                        vivo model pharmacokinetic chemotherapeutic investigations. II. <br /> isolates mutant derivatives 307-0294 cleared                          Microbiological characterization. Infection 11:41&#226;&#8364;&#8220;46. <br /> in soft-tissue infection model cleared as-                       9. Davidson, B., P. Knight, J. Helinski, N. Nader, T. Shanley, K. Johnson. <br />                                                                                        1999. The role tumor necrosis factor-alpha pathogenesis aspira- <br /> sessed pneumonia model (data shown). Although                            tion pneumonitis rats. Anesthesiology 91:486&#226;&#8364;&#8220;499. <br /> did measure host response A. baumannii studies,                     10. Davis, K. A., K. A. Moran, C. K. McAllister, P. J. Gray. 2005. Multidrug- <br /> this soft-tissue infection model previously                      resistant Acinetobacter extremity infections soldiers. Emerg. Infect. Dis. <br />                                                                                        11:1218&#226;&#8364;&#8220;1224. <br /> reported (7, 8). Therefore, soft-tissue infection model                     11. Department Veterans Affairs. 2004. Update Colleagues&#226;&#8364;&#8482; Letter sent <br /> more cost-effective high throughput answering certain                          April 23, 2004 concerning Acinetobacter baumannii. Department Veterans <br /> biologic questions. It appear model                           Affairs, Veterans Health Administration, Washington, DC. <br />                                                                                    12. Ecker, J. A., C. Massire, T. A. Hall, R. Ranken, T. T. Pennella, C. A. Ivy, L. B. <br /> used initial, efficient means assess growth/clear-                       Blyn, S. A. Hofstadler, T. P. Endy, P. T. Scott, L. Lindler, T. Hamilton, C. <br /> ance Acinetobacter vivo.                                                         Gaddy, K. Snow, M. Pe, J. Fishbain, D. Craft, G. Deye, S. Riddell, E. <br />    Although main goal report, interesting                       Milstrey, B. Petruccelli, S. Brisse, V. Harpin, A. Schink, D. J. Ecker, R. <br />                                                                                        Sampath, M. W. Eshoo. 2006. Identification Acinetobacter species and <br /> aspects A. baumannii biology illuminated                           genotyping Acinetobacter baumannii multilocus PCR mass spec- <br /> study. The soft-tissue infection model discriminating                         trometry. J. Clin. Microbiol. 44:2921&#226;&#8364;&#8220;2932. <br /> for growth differences strains vitro serum                     13. Falagas, M. E., E. A. Karveli. 2007. The changing global epidemiology <br />                                                                                        Acinetobacter baumannii infections: development major public <br /> sensitivity testing (Fig. 7 8). This surprising                    health implications. Clin. Microbiol. Infect. 13:117&#226;&#8364;&#8220;119. <br /> the soft-tissue infection model host factors critical protect-                  14. Fournier, P. E., H. Richet. 2006. The epidemiology control of <br /> ing extracellular bacterial pathogens like Acinetobacter                       Acinetobacter baumannii health care facilities. Clin. Infect. Dis. 42:692&#226;&#8364;&#8220; <br />                                                                                        699. <br /> are present including complement, antimicrobial peptides,                      15. Garzoni, C., S. Emonet, L. Legout, R. Benedict, P. Hoffmeyer, L. Bernard, <br /> professional phagocytes. Second, A. baumannii strains 307-                             J. Garbino. 2005. Atypical infections tsunami survivors. Emerg. In- <br />                                                                                        fect. Dis. 11:1591&#226;&#8364;&#8220;1593. <br /> 0294 853 blood isolates displayed diamet-                        16. Gaynes, R., J. R. Edwards. 2005. Overview nosocomial infections <br /> rically opposed growth/clearance patterns vivo. These data                          caused gram-negative bacilli. Clin. Infect. Dis. 41:848&#226;&#8364;&#8220;854. <br /> highlight fact innate virulence clinical isolates                  17. Jain, R., L. H. Danziger. 2004. Multidrug-resistant Acinetobacter infec- <br />                                                                                        tions: emerging challenge clinicians. Ann. Pharmacother 38:1449&#226;&#8364;&#8220;1459. <br /> may necessarily predicted site isolation.                             18. Johnson, E. N., T. C. Burns, R. A. Hayda, D. R. Hospenthal, C. K. <br />    In summary, supported hypotheses utility                         Murray. 2007. Infectious complications open type III tibial fractures <br /> of rat pneumonia soft-tissue infection models studying                         combat casualties. Clin. Infect. Dis. 45:409&#226;&#8364;&#8220;415. <br />                                                                                    19. Joly-Guillou, M. L. 2005. Clinical impact pathogenicity Acineto- <br /> Acinetobacter biology. Both models described                            bacter. Clin. Microbiol. Infect. 11:868&#226;&#8364;&#8220;873. <br /> report clinically relevant possess certain advantages                      20. Joly-Guillou, M. L., M. Wolff, R. Farinotti, A. Bryskier, C. Carbon. 2000. <br /> over previously described models. These models used                          In vivo activity levofloxacin combination imipenem or <br />                                                                                        amikacin mouse model Acinetobacter baumannii pneumonia. J. An- <br /> study innate virulence various Acinetobacter clinical iso-                      timicrob. Chemother. 46:827&#226;&#8364;&#8220;830. <br /> lates assess potential virulence factors, vaccine candi-                    21. Joly-Guillou, M. L., M. Wolff, J. J. Pocidalo, F. Walker, C. Carbon. 1997. <br /> dates, drug targets vivo used pharmaco-                          Use new mouse model Acinetobacter baumannii pneumonia eval- <br />                                                                                        uate postantibiotic effect imipenem. Antimicrob. Agents Chemother. <br /> kinetic chemotherapeutic investigations.                                           41:345&#226;&#8364;&#8220;351. <br />                                                                                    22. Knapp, S., C. W. Wieland, S. Florquin, R. Pantophlet, L. Dijkshoorn, N. <br />                         ACKNOWLEDGMENTS                                                Tshimbalanga, S. Akira, T. van der Poll. 2006. Differential roles of <br />                                                                                        CD14 toll-like receptors 4 2 murine Acinetobacter pneumonia. <br />   We gratefully acknowledge financial support VA Merit                        Am. J. Respir. Crit. Care Med. 173:122&#226;&#8364;&#8220;129. <br /> Review Department Veterans Affairs (T.A.R.) US                   23. Landman, D., J. M. Quale, D. Mayorga, A. Adedeji, K. Vangala, J. Ravis- <br /> Army Medical Research Acquisition Activity contract                              hankar, C. Flores, S. Brooks. 2002. Citywide clonal outbreak mul- <br />                                                                                        tiresistant Acinetobacter baumannii Pseudomonas aeruginosa Brooklyn, <br /> W81XWH-05-1-0627 (T.A.R. A.C.).                                                    N.Y.: preantibiotic era returned. Arch. Intern. Med. 162:1515&#226;&#8364;&#8220;1520. <br />                                                                                    24. Maegele, M., S. Gregor, E. Steinhausen, B. Bouillon, M. M. Heiss, W. <br />                                REFERENCES                                              Perbix, F. Wappler, D. Rixen, J. Geisen, B. Berger-Schreck, R. Schwarz. <br /> 1. Anstey, N. M., B. J. Currie, M. Hassell, D. Palmer, B. Dwyer, H. Seifert.       2005. The long-distance tertiary air transfer care tsunami victims: <br />    2002. Community-acquired bacteremic Acinetobacter pneumonia tropical             injury <span id='am-81' about='xsp:pattern' typeof='owl:Thing'>pattern</span> microbiological psychological aspects. Crit. Care <br />    Australia caused diverse strains Acinetobacter baumannii, car-        Med. 33:1136&#226;&#8364;&#8220;1140. <br />    riage throat at-risk groups. J. Clin. Microbiol. 40:685&#226;&#8364;&#8220;686.          25. Montero, A., J. Ariza, X. Corbella, A. Domenech, C. Cabellos, J. Ayats, F. <br /> 2. Anstey, N. M., B. J. Currie, K. M. Withnall. 1992. Community-acquired           Tubau, C. Borraz, F. Gudiol. 2004. Antibiotic combinations serious <br />    Acinetobacter pneumonia Northern Territory Australia. Clin. In-           infections caused carbapenem-resistant Acinetobacter baumannii a <br />    fect. Dis. 14:83&#226;&#8364;&#8220;91.                                                                mouse pneumonia model. J. Antimicrob. Chemother. 54:1085&#226;&#8364;&#8220;1091. <br /> 3. Bergogne-Berezin, E., K. J. Towner. 1996. Acinetobacter spp. noso-       26. Pachon-Ibanez, M. E., F. Fernandez-Cuenca, F. Docobo-Perez, J. Pachon, <br />    comial pathogens: microbiological, clinical, epidemiological features.          A. Pascual. 2006. Prevention rifampicin resistance Acinetobacter <br />    Clin. Microbiol. Rev. 9:148&#226;&#8364;&#8220;165.                                                    baumannii experimental pneumonia murine model, using rifampicin <br />  3586         RUSSO ET AL.                                                                                                                                 INFECT. IMMUN. <br />  <br />       associated imipenem sulbactam. J. Antimicrob. Chemother. 58:689&#226;&#8364;&#8220;                model gram-negative bacterial pneumonia. Am. J. Physiol. Lung Cell. <br />       692.                                                                                    Mol. Physiol. 283:L655&#226;&#8364;&#8220;L663. <br /> 27.   Pantopoulou, A., E. J. Giamarellos-Bourboulis, M. Raftogannis, T. Tsaga-          40.   Russo, T. A., B. A. Davidson, J. M. Beanan, R. Olson, B. A. Holm, R. H. <br />       nos, I. Dontas, P. Koutoukas, F. Baziaka, H. Giamarellou, D. Perrea.                Notter, P. R. Knight III. 2007. Capsule O-antigen extraint- <br />       2007. Colistin offers prolonged survival experimental infection multi-            estinal isolate Escherichia coli modulate cytokine levels rat macro- <br />       drug-resistant Acinetobacter baumannii: significance co-administration           phages vitro rat model pneumonia. Exp. Lung Res. 33:337&#226;&#8364;&#8220;356. <br />       rifampicin. Int. J. Antimicrob. Agents 29:51&#226;&#8364;&#8220;55.                               41.   Russo, T. A., B. A. Davidson, U. B. Carlino-MacDonald, J. D. Helinski, R. L. <br /> 28.   Paterson, D. L., Y. Doi. 2007. A step closer extreme drug resistance             Priore, P. R. Knight III. 2003. The effects Escherichia coli capsule, <br />       (XDR) gram-negative bacilli. Clin. Infect. Dis. 45:1179&#226;&#8364;&#8220;1181.                        O-antigen, host neutrophils, complement rat model Gram- <br /> 29.   Perez, F., A. M. Hujer, K. M. Hujer, B. K. Decker, P. N. Rather, R. A.              negative pneumonia. FEMS Microbiol. Lett. 226:355&#226;&#8364;&#8220;361. <br />       Bonomo. 2007. Global challenge multidrug-resistant Acinetobacter bau-          42.   Russo, T. A., B. A. Davidson, S. A. Genagon, N. M. Warholic, U. Macdonald, <br />       mannii. Antimicrob. Agents Chemother. 51:3471&#226;&#8364;&#8220;3484.                                     P. D. Pawlicki, J. M. Beanan, R. Olson, B. A. Holm, P. R. Knight III. <br /> 30.   Petersen, K., M. S. Riddle, J. R. Danko, D. L. Blazes, R. Hayden, S. A.                 2005. E. coli virulence factor hemolysin induces neutrophil apoptosis and <br />       Tasker, J. R. Dunne. 2007. Trauma-related infections battlefield                 necrosis/lysis vitro necrosis/lysis lung injury rat pneumonia <br />       casualties Iraq. Ann. Surg. 245:803&#226;&#8364;&#8220;811.                                           model. Am. J. Physiol. Lung Cell. Mol. Physiol. 289:L207&#226;&#8364;&#8220;L216. <br /> 31.   Renckens, R., J. J. Roelofs, S. Knapp, A. F. Vos, S. Florquin, T. van      43.   Russo, T. A., M. C. Moffitt, C. H. Hammer, M. M. Frank. 1993. TnphoA- <br />       der Poll. 2006. The acute-phase response serum amyloid A inhibit                mediated disruption K54 capsular polysaccharide genes Escherichia coli <br />       inflammatory response Acinetobacter baumannii pneumonia. J. Infect. Dis.             confers serum sensitivity. Infect. Immun. 61:3578&#226;&#8364;&#8220;3582. <br />       193:187&#226;&#8364;&#8220;195.                                                                      44.   Scott, P., G. Deye, A. Srinivasan, C. Murray, K. Moran, E. Hulten, J. <br />                                                                                               Fishbain, D. Craft, S. Riddell, L. Lindler, J. Mancuso, E. Milstrey, C. T. <br /> 32.   Rice, L. B. 2006. Challenges identifying new antimicrobial agents effective <br />                                                                                               Bautista, J. Patel, A. Ewell, T. Hamilton, C. Gaddy, M. Tenney, G. Chris- <br />       treating infections Acinetobacter baumannii Pseudomonas <br />                                                                                               topher, K. Petersen, T. Endy, B. Petruccelli. 2007. An outbreak of <br />       aeruginosa. Clin. Infect. Dis. 43:S100&#226;&#8364;&#8220;S105. <br />                                                                                               multidrug-resistant Acinetobacter baumannii-calcoaceticus complex infection <br /> 33.   Richet, H., P. E. Fournier. 2006. Nosocomial infections caused Acin- <br />                                                                                               US military health care associated military operations in <br />       etobacter baumannii: major threat worldwide. Infect. Control Hosp. Epi- <br />                                                                                               Iraq. Clin. Infect. Dis. 44:1577&#226;&#8364;&#8220;1584. <br />       demiol. 27:645&#226;&#8364;&#8220;646. <br />                                                                                         45.   Sunenshine, R. H., M. O. Wright, L. L. Maragakis, A. D. Harris, X. Song, <br /> 34.   Rodriguez-Hernandez, M. J., L. Cuberos, C. Pichardo, F. J. Caballero, I.                J. Hebden, S. E. Cosgrove, A. Anderson, J. Carnell, D. B. Jernigan, D. G. <br />       Moreno, M. E. Jimenez-Mejias, A. Garcia-Curiel, J. Pachon. 2001.                    Kleinbaum, T. M. Perl, H. C. Standiford, A. Sri <br /> </body></html>